Mer­ck vet Michael Rosen­blatt joins R&D ex­o­dus to the start­up world

Mer­ck Chief Med­ical Of­fi­cer Michael Rosen­blatt re­cent­ly caused quite a stir when he sug­gest­ed that a lot of aca­d­e­m­ic re­search work in the drug field is a mess, urg­ing that in­ves­ti­ga­tors be forced to re­turn at least some of their fund­ing if in­dus­try sci­en­tists can’t re­pro­duce their work.

And now, Rosen­blatt will get to ex­plain his po­si­tion on a face-to-face ba­sis.

Cam­bridge, MA-based Flag­ship Ven­tures, which has been soak­ing up aca­d­e­m­ic re­search in its quest to start up a string of new biotechs, has named Rosen­blatt as its very first CMO. And he’s been tapped to play a lead­ing role in spawn­ing a new wave of up­starts at Flag­ship.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.